Skip to content
Open access

Multimodal artificial intelligence for personalized hepatocellular carcinoma treatment strategy selection

Aug 2026 · medRxiv · 0 citations
Medicine

TL;DR

Embedding-Augmented Extra Trees (ET-Emb), a novel model fusing structured clinical variables with contextual text embeddings derived from medical histories and radiology reports, delivers accurate, multi-treatment strategy prediction for HCC.

Abstract

Background Hepatocellular carcinoma (HCC) treatment selection demands nuanced integration of heterogeneous patient data, yet prevailing predictive models rely on restricted data modalities and oversimplified therapeutic frameworks, compromising clinical translation. Objective We developed and validated a multimodal artificial intelligence framework to guide optimal treatment strategy selection across the full spectrum of HCC interventions. Methods This retrospective study comprised 1,043 HCC patients (development cohort, January 2017-December 2023) and 55 external validation patients (2023) from Wuxi Peoples Hospital. We engineered Embedding-Augmented Extra Trees (ET-Emb), a novel model fusing structured clinical variables with contextual text embeddings derived from medical histories and radiology reports. ET-Emb quantifies probabilities for five primary treatments: open/laparoscopic resection, transarterial chemoembolization, radiofrequency ablation (RFA), and chemotherapy. Model performance was rigorously assessed via 10-fold cross-validation and external validation using ROC-AUC and PR-AUC metrics. Results ET-Emb demonstrated robust performance in the development cohort (ROC-AUC: 0.84 {+/-} 0.04; PR-AUC: 0.55 {+/-} 0.06), significantly outperforming established benchmarks. This generalizability was preserved in external validation (ROC-AUC: 0.77 {+/-} 0.02; PR-AUC: 0.47 {+/-} 0.03). SHAP analysis identified textual clinical narratives and socioeconomic determinants as critical predictive drivers. Conclusions By unifying structured and unstructured data modalities, ET-Emb delivers accurate, multi-treatment strategy prediction for HCC. Its clinical validity and the demonstrated significance of textual features establish multimodal AI as an essential paradigm for simulating complex oncological decision-making, positioning ET-Emb as a transformative tool for precision HCC management.

Read PDF

Similar papers

Review Open access Oct 2026

Artificial Intelligence in Precision Oncology Clinical Applications, Translational Challenges, and Future Directions

Background: Precision oncology aims to individualize cancer prevention, diagnostic stratifications, prognostication, and therapeutic regimens by synthesizing tumor biology with patient-specific clinical, demographic, and multi-omic characteristics. The exponential volume, velocity, and multi-scale complexity of contemp...

Goil Abhishek, Nrip Nripesh Kumar · 0 citations
Review Open access Aug 2026

Multimodal artificial intelligence and machine learning in oncology: from data integration to precision cancer care

The role of multimodal artificial intelligence and machine learning in bridging the gap in interpreting heterogeneous modalities to improve risk prediction, prognostic assessment, and treatment decision-making in precision oncology is focused on.

Shruthi Suresh, A. Parvathy, Megha Raj et al. · 0 citations
Review Open access Sep 2026

Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma

Abstract Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality and arises predominantly in cirrhotic livers, making prognosis and treatment response highly dependent on hepatic reserve and comorbidity. With multiple first-line immunotherapy and anti-VEGF based regimens, real-world decision making r...

A. Syed, M. Akce, Midhun Malla · 0 citations
Sep 2026

Breast Cancer Recurrence Status Assessment in 5 Years Using Multimodal Integrated Learning: A Feasibility Study.

The findings underscore the potential of the proposed multimodal deep learning framework to provide accessible, accurate, and generalizable recurrence risk prediction using routinely available clinical data, potentially supporting more informed treatment decisions and personalized post-treatment monitoring in real-worl...

R. Chang, Hsiang-Wei Huang, Szu-Yen Kuo et al. · 0 citations
Open access Oct 2026

Knowledge-guided Multimodal Learning for Interpretable Prediction of Pathological Complete Response and Survival in Breast Cancer.

PURPOSE Pretreatment estimation of pathological complete response (pCR) to neoadjuvant chemotherapy may support risk stratification and future response-adapted clinical studies in breast cancer. However, existing deep learning approaches often rely on "black-box" visual pattern recognition, suffering from poor interpre...

Wen-Chuan Zhang, Shu-Wan Zhang, Ya-Ni Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.